Dupont Jakob 4
4 · Pyxis Oncology, Inc. · Filed Aug 25, 2023
Insider Transaction Report
Form 4
Dupont Jakob
Director
Transactions
- Award
Stock Option (Right to buy)
2023-08-23+17,250→ 17,250 totalExercise: $15.37Exp: 2032-09-29→ Common Stock (17,250 underlying) - Award
Stock Option (Right to buy)
2023-08-23+5,879→ 5,879 totalExercise: $26.61Exp: 2030-09-01→ Common Stock (5,879 underlying) - Award
Stock Option (Right to buy)
2023-08-23+3,534→ 3,534 totalExercise: $26.61Exp: 2031-02-12→ Common Stock (3,534 underlying)
Footnotes (2)
- [F1]The shares subject to this option vested in full immediately prior to the closing of the merger described in footnote 2.
- [F2]On May 23, 2023, the Issuer, Ascent Merger Sub Corp., a wholly-owned subsidiary of the Issuer, or the Merger Sub, and Apexigen, Inc., or Apexigen, entered into a definitive agreement for the Issuer to acquire Apexigen, or the Merger Agreement. Under the terms of the Merger Agreement, the reporting person's options to purchase shares of Apexigen Common Stock, or the Apexigen Options, that were outstanding immediately prior to the effective time of the merger were assumed by the Issuer and converted into options to acquire, on substantially similar terms and conditions, the number of shares of the Issuer Common Stock determined by multiplying the number of shares subject to the Apexigen Options by 0.1725, or the Exchange Ratio, shares of the Issuer Common Stock, rounded down to the nearest whole share, with an exercise price per share equal to the exercise price per share of such Apexigen Option divided by the Exchange Ratio, rounded up to the nearest whole cent.